By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

CoLucid Pharmaceuticals, Inc. 

902 North Capitol Avenue
Suite 302
Indianapolis  Indiana  46204  U.S.A.
Phone: 317-684-6703 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
CoLucid Pharmaceuticals, Inc. Announces Agreement From The FDA On A Special Protocol Assessment (SPA) For The Phase 3 Trial Of Lasmiditan In Migraine Including Patients With Risk Factors For Cardiovascular Disease 5/7/2014 8:19:43 AM
CoLucid Pharmaceuticals, Inc. and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine 10/23/2013 9:51:59 AM
CoLucid Pharmaceuticals, Inc. Release: New Study Results Regarding Cardiovascular Contraindications to Triptans in the Migraine Population to be Presented at the 16th Congress of the International Headache Society, June 30, in Boston, MA 6/27/2013 6:44:19 AM
CoLucid Pharmaceuticals, Inc. Release: New Study Shows That Majority of Acute Migraine Patients Have Cardiovascular Disease Risk Factors and One Third Have Cardiovascular Disease 12/21/2012 8:22:50 AM
CoLucid Pharmaceuticals, Inc. to Attend the BIO-Europe 2012 Meeting in Hamburg, Germany 11/8/2012 10:03:01 AM
CoLucid Pharmaceuticals, Inc. Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy 9/18/2012 10:29:01 AM
CoLucid Pharmaceuticals, Inc. Founder Passes Away 2/8/2012 6:49:13 AM
CoLucid Pharmaceuticals, Inc. to Present at the Biotech Showcase During J.P. Morgan Healthcare Conference 1/4/2012 1:31:25 PM
CoLucid Pharmaceuticals, Inc. to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan 9/29/2011 11:51:10 AM
CoLucid Pharmaceuticals, Inc. Announces Study Data Documenting Oral Efficacy of Lasmiditan (COL-144), a Selective 5-HT1F Receptor Agonist, in the Treatment of Acute Migraine Attacks 6/9/2010 11:06:50 AM
12
//-->